Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors
Najam A.Sharif
Department of Pharmaceutical Sciences,College of Pharmacy and Health Sciences,Texas Southern University,Houston,TX,USA;Department of Pharmacology and Neuroscience,University of North Texas Health Sciences Center,Fort Worth,TX,USA;Department of Pharmacy Sciences,School of Pharmacy and Health Professions,Creighton University,Omaha,NE,USA;Singapore Eye Research Institute(SERI),Singapore,Singapore;Duke-NUS Medical School,Singapore,Singapore;Department of Surgery&Cancer,Imperial College of Science and Technology,St.Mary's Campus,London,UK;Global Alliances and External Research,Ophthalmology Innovation Center,Santen Inc USA,Emeryville,CA,USA
摘要：Cellular and mitochondrial membrane phospholipids provide the substrate for synthesis and release of prostaglandins in response to certain chemical, mechanical, noxious and other stimuli. Prostaglandin D2, prostaglandin E2, prostaglandin F2α, prostaglandin I2 and thromboxane-A2 interact with five major receptors (and their sub-types) to elicit specific downstream cellular and tissue actions. In general, prostaglandins have been associated with pain, inflammation, and edema when they are present at high local concentrations and involved on a chronic basis. However, in acute settings, certain endogenous and exogenous prostaglandins have beneficial effects ranging from mediating muscle contraction/relaxation, providing cellular protection, regulating sleep, and enhancing blood flow, to lowering intraocular pressure to prevent the development of glaucoma, a blinding disease. Several classes of prostaglandins are implicated (or are considered beneficial) in certain central nervous system dysfunctions (e.g., Alzheimer's, Parkinson's, and Huntington's diseases; amyotrophic lateral sclerosis and multiple sclerosis; stroke, traumatic brain injuries and pain) and in ocular disorders (e.g., ocular hypertension and glaucoma; allergy and inflammation; edematous retinal disorders). This review endeavors to address the physiological/pathological roles of prostaglandins in the central nervous system and ocular function in health and disease, and provides insights towards the therapeutic utility of some prostaglandin agonists and antagonists, polyunsaturated fatty acids, and cyclooxygenase inhibitors.
机标关键词：
论文发表日期：2023-01-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：13( 5-17 )
英文信息